Reduced corticosteroid use in adult patients with primary immune thrombocytopenia receiving romiplostim

Hematology

Volumn 16, Issue 5, 2011, Pages 274-277

  Michel, Marc ^a   te Boekhorst, Peter A W ^b   Janssens, Ann ^c   Pabinger Fasching, Ingrid ^d   Sanz, Miguel A ^e   Nie, Kun ^f   Kreuzbauer, Georg ^f  

^a HENRI MONDOR HOSPITAL   (France)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e HOSPITAL UNIVERSITARIO LA FE   (Spain)

^f AMGEN INC   (United States)

Author keywords

Corticosteroids; ITP; Primary immune thrombocytopenia; Romiplostim

Indexed keywords

CORTICOSTEROID; PLACEBO; PREDNISONE; ROMIPLOSTIM;

ADULT; AGED; ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RETROSPECTIVE STUDY; TREATMENT DURATION;

ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; RECEPTORS, FC; RECEPTORS, THROMBOPOIETIN; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA; THROMBOPOIETIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80052572964     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453311X13025568942005     Document Type: Article

References (14)

1. Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113:2386-93.
2. Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115:168-86.
3. Arnold DM, Kelton JG. Current options for the treatment of idiopathic thrombocytopenic purpura. Semin Hematol 2007; 44:S12-S23.
4. Stasi R, Evangelista ML, Amadori S. Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura. Drugs 2008;68:901-12.
5. McDonough AK, Curtis JR, Saag KG. The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol 2008;20:131-7.
6. Mathias SD, Gao SK, Miller KL, Cella D, Snyder C, Turner R, et al. Impact of chronic Immune Thrombocytopenic Purpura (ITP) on health-related quality of life: a conceptual model starting with the patient perspective. Health Qual Life Outcomes 2008;6:13.
7. Nugent D, McMillan R, Nichol JL, Slichter SJ. Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production. Br J Hematol 2009;146:585-96.
8. Newland A. Thrombopoietin receptor agonists in the treatment of thrombocytopenia. Curr Opin Hematol 2009;16:357-64.
9. Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009;113:2161-71.
10. Kuter DJ, Bussel JB, Newland A, Wasser JS, Lyons RM, George JN, et al. Long-term efficacy and safety of romiplostim treatment of adult patients with chronic immune thrombocytopenia (ITP): final report from an open-label extension study. ASH Annual Meeting Abstracts 2010;116:Abstract 68.
11. Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008;37:395-403.
12. Michel M, Desborough C. Reduced corticosteroid treatment in adults with ITP receiving romiplostim. EHA Annual Meeting Abstracts 2009; 0226.
13. Kuter DJ, Bussel JB, Newland A, de Wolf JTM, Guthrie T, Wasser J, et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenic purpura (ITP): 3-year update from an open-label extension study. ASH Annual Meeting Abstracts 2008;112:402.
14. Pullarkat VA, Gernsheimer TB, Wasser JS, Newland A, Guthrie TH Jr, de Wolf JT, et al. Quantifying the reduction in immunoglobulin use over time in patients with chronic immune thrombocytopenic purpura receiving romiplostim (AMG 531). Am J Hematol 2009;84:538-40.